Covid-19 roundup: As­traZeneca launch­es new virus R&D di­vi­sion; US buys more of Mer­ck­'s an­tivi­ral pill

As­traZeneca is launch­ing a new di­vi­sion to en­com­pass its vac­cine and an­ti­bod­ies busi­ness­es.

The sub­unit will fo­cus on its Covid-19 vac­cine and long-act­ing an­ti­body com­bi­na­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER